spartalizumab

Overview

Spartalizumab is an anti-PD-1 monoclonal antibody targeting PDCD1. It was evaluated as an immune checkpoint inhibitor in hepatocellular carcinoma (HCC).

Evidence in the corpus

• Listed as an investigational anti-PD-1 immune checkpoint inhibitor in the context of HCC immunotherapy strategies discussed in a comprehensive HCC molecular landscape review PMID:24798001.

Resistance mechanisms

Cancer types (linked)

• HCC

Sources

This page was processed by entity-page-writer on 2026-05-11.